ADapt

Lifestyle & Health slider
Lilly’s EBGLYSS® (lebrikizumab-Ibkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

by Karine Ayoub March 20, 2025

by Karine Ayoub March 20, 2025

Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of…

0 Facebook Twitter Pinterest Email

Weekly Notification

Bulletin’s Archive

Search Bulletins

Tags

Abu Dhabi Ports American University of Beirut American University of Sharjah (AUS) AUB aubmc Bank Audi Blom Bank Breitling Byblos Bank cannes lions Corona Virus (COVID-19) COVID-19 Corona Elie Saab Emirates Ericsson Garena Free Fire Gartner Global Village Globemed Grohe Huawei Hyundai Kandima Maldives Kia Kia Corporation LAU Medical Center Rizk Hospital LG LG Electronics Maserati Mastercard NISSAN PRCA MENA Ralph & Russo Ramadan Rebirth Beirut Salesforce Samsung SAP Starzplay Tony Ward UN UNICEF United Nations VFS Global Zuhair Murad

THE BULLETIN

All press releases and company news, brochures, logos, videos, images, and brands are property of their respective owners and not the bulletin.
All press releases and company news, brochures, logos, videos, images, and brands references used in this website are for identification and informational purposes only.
Use of these press releases and company news, brochures, logos, videos, images, and brands does not imply endorsement by, sponsorship by, or affiliation with the bulletin.

JOIN US

About us
Contact us
HOME

Keep in touch

Facebook

ADapt

Lilly’s EBGLYSS® (lebrikizumab-Ibkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis